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ABSTRACT
Apurinic/apyrimidinic endonuclease-1 (APE1) is an
essential enzyme in the base excision repair (BER)
pathway. Here, we show that APE1 is a target of
the SIRTUIN1 (SIRT1) protein deacetylase. SIRT1
associates with APE1, and this association is
increased with genotoxic stress. SIRT1 deacetylates
APE1 in vitro and in vivo targeting lysines 6 and 7.
Genotoxic insults stimulate lysine acetylation
of APE1 which is antagonized by transcriptional
upregulation of SIRT1. Knockdown of SIRT1
increases cellular abasic DNA content, sensitizing
cells to death induced by genotoxic stress, and
this vulnerability is rescued by overexpression
of APE1. Activation of SIRT1 with resveratrol
promotes binding of APE1 to the BER protein
X-ray cross-complementing-1 (XRCC1), while inhibi-
tion of SIRT1 with nicotinamide (NAM) decreases
this interaction. Genotoxic insult also increases
binding of APE1 to XRCC1, and this increase is sup-
pressed by NAM or knockdown of SIRT1. Finally,
resveratrol increases APE activity in XRCC1-
associated protein complexes, while NAM or knock-
down of SIRT1 suppresses this DNA repair activity.
These findings identify APE1 as a novel protein
target of SIRT1, and suggest that SIRT1 plays a
vital role in maintaining genomic integrity through
regulation of the BER pathway.
INTRODUCTION
The major mammalian Apurinic/apyrimidinic endo-
nuclease APE1, also known as Redox Factor-1 (Ref-1),
is a multifunctional protein. It plays a vital role in the
repair of single-strand DNA breaks induced by oxidative
and alkylating agents, abasic sites generated during the
repair of DNA bases chemically modiﬁed by such
genotoxic agents, and spontaneously generated abasic
DNA sites (1–4). In this essential role in the base
excision repair (BER) pathway, APE1 interacts with
other DNA repair proteins including DNA polymerase
b (Polb) (5), ﬂap endonuclease-1 (FEN1) (6), and X-ray
cross-complementing-1 (XRCC1) (6). In addition to this
DNA repair function, APE1, through its properties as a
reducing protein, has been identiﬁed as an activator of
several redox (reduction-oxidation)-sensitive transcription
factors including p53 (7), AP-1 (8), and NF-kB (9). The
ﬁnal known function of APE1 relates to its identiﬁca-
tion as one of the proteins that binds to negative
calcium-response elements (nCaREs) in the parathyroid
hormone (PTH) and renin genes, down-regulating their
transcription in response to increase in extracellular
calcium (10,11).
Independent of transcriptional control, APE1 is
regulated by many post-translational modiﬁcations with
some of these modiﬁcations having an impact on one or
more of its functions. Casein kinase II (CKII)-mediated
phosphorylation impairs the DNA repair activity of the
protein (12), while stimulating its redox function toward
the AP-1 transcription complex (13). Protein kinase C
(PKC) phosphorylates APE1 as well, also stimulating its
ability to promote DNA binding of AP-1 (14). The
nuclear export of APE1 is regulated by S-nitrosylation
of cysteines 93 and 310 (15). In addition, APE1 is
targeted by the cellular acetylation-deacetylation machin-
ery. APE1 is acetylated by the p300 acetyltransferase on
lysines 6 and 7, and this acetylation enhances its binding
to the nCaRE in the PTH promoter, stimulating PTH
promoter activity (16). Moreover, acetylated APE1 has
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of phosphinositol phosphatase and tensin homologue
(PTEN) (17), a negative regulator of the phosphoinositide
3-kinase/Akt signaling pathway. Although studies
have demonstrated that APE1 binds to class I histone
deacetylases (HDAC), the role of these HDAC in
deacetylating APE1 has not been examined. Furthermore,
although APE1 does not appear to bind to class II
HDAC, its association with class III HDACs, as well as
the role of class III HDAC in regulating its acetylation has
not been reported.
SIRTUIN 1 (SIRT1) is a class III HDAC. It is the
closest mammalian ortholog of yeast silent information
regulator (sir2) protein which senses changes in energy
availability and responds by regulating metabolic
pathways (18). SIRT1 expression and function are
regulated by external stressors including a decrease in
available nutrition and genotoxic agents (19,20). In
response to such stressors, SIRT1 not only orchestrates
transcription through its function as a histone deacetylase,
but also deacetylates many non-histone proteins that
are important in regulating energy metabolism and stress
response such as p53 (21,22), nuclear factor-kB (23),
peroxisome proliferator-activated receptor-g (PPAR-g)
(24), and PPAR-g coactivator-1a (PGC-1a) (25).
Although SIRT1 aﬀects the cell cycle and promotes
stress resistance in response to cytotoxic stimuli
(21,26–28), few substrates of SIRT1 have been identiﬁed
that are directly involved in the maintenance of genomic
integrity. A recent report shows that SIRT1, by directly
targeting Nijmegen Breakage syndrome (NBS1) protein
for deacetylation and thereby facilitating its phos-
phorylation by the ataxia telangiectasia mutated (ATM)
protein kinase, plays a central role in the cellular response
to agents that cause double-stranded DNA breaks (29).
To identify other DNA repair proteins that are novel
targets for deacetylation by SIRT1 we investigated the
possibility that SIRT1 deacetylates APE1, and thereby
has an important part in the cellular BER pathway.
MATERIALS AND METHODS
Materials
Antibodies against SIRT1, APE1, Myc-tag and p300 were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Antibodies against acetyl-lysine, Ac-K 382-p53 and
XRCC1 were purchased from Cell Signaling Technology
(Beverly, MA). Monoclonal antibody against FLAG-tag
was from Sigma-Aldrich (St Louis, MO). All reagents
were obtained from Sigma-Aldrich unless otherwise
stated.
Cell culture
HEK 293 cells and HeLa cells were obtained from ATCC
(Manassas, VA). Cells were maintained at 37 Ci n5 %
CO2 in DMEM (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum. Transfection of plasmid
and/or RNAi was accomplished using LipofectAMINE
2000 (Invitrogen) according to the manufacturer’s
instructions. Approximately 2mg of plasmid DNA was
transfected per 5 10
6cells (+) or multiples thereof.
Validated Stealth RNAi for APE1 and SIRT1 as well as
the appropriate control scrambled oligonucleotides were
purchased from Invitrogen.
Plasmids
The cDNA of human APE1 was cloned into p3xFLAG-
CMV-7.1 mammalian expression plasmid (Sigma-
Aldrich). The same cDNA was cloned into pET-41b
(Novagen, Madison, WI) for bacterial expression of
APE1 and into pDsRed-N1 (Clonetech, Mountain View,
CA) for cell ﬂuorescence studies. Myc-tagged mammalian
expression vectors carrying human SIRT1 (wild type or
H363Y mutant) were kindly provided by T Kouzarides.
The same human SIRT1 cDNA was cloned into pEGFP-
C2 (Clonetech) for co-localization experiments. The
cDNA of human p300 was a generous gift from
Dr. Wangsen Cao and was cloned into pcDNA 3.1( ).
Microscopy
APE1 cloned into pDsRed-N1 and SIRT1 cloned into
pEGFP-C2 were co-transfected into HEK 293 cells. Red
and green ﬂuorescent images were taken using an Axiovert
200 Fluorescence microscope (Carl Zeiss, Jena, Germany).
Merged images were created using Adobe Photoshop
software.
Co-immunoprecipitation
Cells were collected by brief centrifugation. The pellet was
suspended in IP lysis buﬀer (50mM Tris–HCl (pH 7.5),
1% (v/v) Triton X-100, 5% (v/v) glycerol, 5mM EDTA,
150mM NaCl, 10mM NaF, 1mM PMSF, 1  protease
inhibitor cocktail (Roche Applied Science, Indianapolis,
IN), 10mM nicotinamide (NAM), 5mM trichostatin A
(TSA)) and incubated for 20min on ice. After
centrifugation (14000 g, 15min, 4 C), cell lysates were
collected and protein concentration was determined by
Bio-Rad Protein Assay reagent (Bio-Rad, Hercules,
CA). Cell lysates were incubated with 2mg of antibody
for 16–20h at 4 C followed by the addition of 20mlo f
Protein-A or -G Sepharose beads (50% slurry). After
further 2h incubation at 4 C, beads were washed four
times with IP lysis buﬀer and then washed once with
PBS. Samples were mixed with 2  SDS sample buﬀer
and subjected to SDS–PAGE, followed by immu-
noblotting using the speciﬁed primary antibody and the
appropriate secondary antibody.
In vitro APE1 acetylation/deacetylation
Recombinant human APE1 protein was expressed in
BL21 (DE3) Escherichia coli (Stratagene, La Jolla, CA)
as GST fusion protein. GST-APE1 protein was puriﬁed
using Glutathione Sepharose 4B beads (GE Healthcare
Bio-Sciences, Piscataway, NJ). GST portion was cleaved
oﬀ by Thrombin Clean Cleave Kit (Sigma) and removed
using Glutathione Sepharose 4B beads. After exchanging
the buﬀer with 50mM Tris–HCl (pH 8.0), protein concen-
tration was determined.
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200ng of p300 acetyltransferase (Active Motif, Carlsbad,
CA) in acetylation buﬀer (50mM Tris–HCl (pH 8.0),
0.1mM EDTA, 10% (v/v) glycerol, 1mM DTT, 50mM
AcCoA) for 1h at 30 C with shaking. After the incuba-
tion, the mixture was supplemented with 10units of
SIRT1 (Biomol, Plymouth Meeting, PA), 1mM NAD
+,
150mM NaCl, 3mM KCl, 4mM MgCl2 to initiate the
deacetylation reaction. The deacetylation reaction was
performed with or without 1mM TSA or 10mM NAM.
After the incubation for 90min at 37 C, the reaction was
terminated by adding 3  SDS sample buﬀer and samples
were subjected to SDS–PAGE and immunoblotting to
evaluate APE1 acetylation.
In vivo APE1 acetylation/deacetylation
Cells were collected by brief centrifugation. The pellet was
suspended in pre-boiled (10min) denaturing cell lysis
b u ﬀ e r[ 5 0m MT r i s – H C l( p H7 . 4 ) ,1m ME D T A ,1 %( w / v )
SDS, 70 mM b-ME] and was boiled for another 10min.
After sonication (15s 3) and following centrifugation
(14000 g, 15min, 4 C), supernatants were transferred
to new tubes. The samples were diluted by the addition
of 9vol of IP lysis buﬀer and protein concentration was
determined. Three mg of APE1 antibody was added to the
samples containing equal amount of protein, and rotated
overnight at 4 C. After adding 30ml of Protein
G-Sepharose beads (50% slurry) samples were rotated
for 3–6h at 4 C. Beads were washed four times with IP
lysis buﬀer and then washed once with PBS. Thirty
microliters of 2  SDS sample buﬀer was added to the
beads and boiled for 5min. Samples were subjected to
SDS–PAGE and immunoblotting using acetyl-lysine
antibody to evaluate APE1 acetylation.
Real-time PCR
Total RNA from cells was isolated by the acid
guanidinium thiocyanate/phenol/chloroform method.
Real time PCR was performed using the Prism 7000
Sequence Detection System (Applied Biosystems) with
the SuperScript III Platinum SYBR Green One-Step
qRT-PCR Kit (Invitrogen). The primer sequences for
human SIRT1 are: forward 50-TCGCAACTATACCCA
GAACATAGACA-30, reverse 50-CTGTTGCAAAGGA
ACCATGACA-30. Human GAPDH was used as an
internal control. The primer sequences for human
GAPDH are: forward 50-ATG ACA TCA AGA AGG
TGG TG-30, reverse 50-CAT ACC AGG AAA ATG
AGC TTG-30. Dissociation curves were monitored to
check the aberrant formation of primer-dimers.
Promoter-reporter assay
A 1403 base pair fragment of the human SIRT1 promoter
(–1266 to +137 relative to transcription start site) was
cloned into the pGL4.1 ﬁreﬂy luciferase reporter vector
(Promega). The SIRT1 promoter-reporter plasmid was
co-transfected with a constitutive renilla reporter
plasmid using Lipofectamine2000 (Invitrogen) as per man-
ufacturer’s recommendations. Fireﬂy and renilla luciferase
activity were measured using the Dual Luciferase reporter
kit (Promega) as per manufacturer’s recommendations,
and ﬁreﬂy activity was normalized to renilla activity to
correct for diﬀerences in transfection eﬃciency. Results
presented are from a representative experiments per-
formed in triplicate.
Apoptosis
Apoptotic cell death was quantiﬁed using Cell Death
Detection ELISA kit (Roche) according to the manufac-
turer’s instructions.
AP sites
Apurinic/apyrimidinic (AP) sites were quantiﬁed using
the DNA Damage Quantiﬁcation kit (Oxford Biomedical
Research, Oxford MI), as per manufacturer’s recom-
mendations. This colorimetric kit quantiﬁes apurinic/
apyrimidinic sites by using an aldehyde reactive probe
which tags them with biotin, followed by detection with
HRP-streptavidin.
AP endonuclease activity assay
A 25-mer oligonucleotide containing tetrahydrofuran
(THF; Midland Certiﬁed Reagents, Midland, TX) at
position 15 in the sequence 50-AATTCACCGGTACC
XCCTAGAATTCG-30 (X: THF) was 50-terminally
labeled with [g-
32P]ATP using DNA 50-end-labeling
System (Promega, Madison, WI). The labeled oligo-
nucleotide was annealed to the complementary strand
with T opposite THF and puriﬁed by PAGE.
HeLa cells transfected with Flag-APE1 plasmid and
subsequently treated with NAM (5mM) or resveratrol
(50mM) for6 h were harvested and washed with PBS.
Cells were resuspended in PBS containing 2mM DTT
and pulse-sonicated three times for 15s each. After
centrifugation at 14000 g for 10min at 4 C, protein con-
centration of cell extract was determined by Bio-Rad
Protein Assay reagent. XRCC1 immunoprecipitated
from 1500mg was incubated in a total volume of 20mlo f
assay buﬀer [50mM HEPES–NaOH (pH 7.5), 50mM
KCl, 10mM MgCl2, 1% BSA, 0.05% Triton X-100] con-
taining the labeled duplex oligonucleotide (400fmol) for
10, 20 and 30min at 37 C. Reactions were terminated
by adding 10ml of formamide loading buﬀer (96%
formamide, 10mM EDTA, 0.1% bromophenol blue).
The samples were then heated at 95 C for 5min to
denature the oligonucleotides, and were analyzed on a
20% polyacrylamide, 7M urea gel. After electrophoresis,
the gel was autoradiographed to locate the labeled
substrate and product oligonucleotides. AP endonuclease
activity was similarly performed in vitro using puriﬁed
recombinant GST-tagged APE1 that was acetylated
with recombinant active p300 and deacetylated with
recombinant SIRT1.
RESULTS
APE1 and SIRT1 co-precipitate and co-localize in cells
To examine the relationship between APE1 and SIRT1 we
ﬁrst determined whether there exists a physical association
between the two proteins. Tagged APE1 co-precipitated
834 Nucleic Acids Research, 2010,Vol. 38,No. 3with SIRT1 in HEK293 but not with a catalytically
inactive, dominant negative, SIRT1(H363Y) mutant
(Figure 1A and B). Endogenous SIRT1 also
co-precipitated with endogenous APE1 (Figure 1C).
Moreover, APE1 and SIRT1 co-localized to the nuclei
of HEK 293 cells (Figure 1D). Postulating that this asso-
ciation may have functional relevance, we examined the
eﬀect of genotoxic stress on APE1-SIRT1 binding.
Because APE1 and SIRT1 protect cells against hydrogen
peroxide (H2O2) (30–35), an oxidative stress that leads to
DNA damage resulting in abasic DNA sites (36), we asked
whether H2O2 aﬀects the association between the two
proteins. In HEK 293 cells H2O2 promoted the binding
of APE1 to SIRT1 (Figure 1D), suggesting that this asso-
ciation may have importance in the context of genotoxic
stress. Thus, APE1 and SIRT1 bind to and localize with
each other and genotoxic stress, against which APE1 and
SIRT1 oﬀer protection, increases this association.
SIRT1 deacetylates APE1 in vitro and in vivo
We then asked if SIRT1 targets APE1 for deacetylation.
First, we examined if APE1 is a target of SIRT1
deacetylase activity in vitro. Recombinant APE1 was
enzymatically acetylated with the p300 acetyltransferase
in vitro, followed by incubation with active SIRT1.
SIRT1 in the presence, but not absence of its co-factor
nicotinamide adenine dinucleotide (NAD), deacetylated
acetylated APE1 (Figure 2A). Addition of Trichostatin
A (TSA), a class I and II HDAC inhibitor, to the
reaction mixture did not aﬀect SIRT1-induced
deacetylation of APE1, whereas the SIRT1 inhibitor
nicotinamide (NAM) negated deacetylation of APE1,
indicating that acetylated APE1 is a direct target of
SIRT1. In HEK 293 cells as well, APE1 was acetylated
by overexpression of the p300 acetyltransferase, and this
increase in lysine acetylation was abrogated by
overexpression of SIRT1 (Figure 2B). Similarly, stimula-
tion of endogenous SIRT1 with resveratrol decreased
p300-induced lysine acetylation of APE1 (Figure 2C).
Notwithstanding the limitation that our data do
not allow us to draw conclusions about site-speciﬁc
acetylation and deacetylation, they show that APE1 is
acetylated by the p300 acetyltransferase, and deacetylated
by SIRT1, in vitro and in vivo.
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Figure 1. APE1 and SIRT1 associate with each other. (A) APE1 and SIRT1 bind to each other in HEK 293 cells. Immunoprecipitation of epitope-
tagged SIRT1 co-precipitates epitope-tagged APE1 expressed in HEK 293 cells. (B) APE1 does not bind to catalytically inactive dominant negative
SIRT1. Immunoprecipitation of epitope-tagged APE1 co-precipitates epitope-tagged wild-type SIRT1 but not dominant negative SIRT1 (H363Y)
expressed in HEK 293 cells. (C) Endogenous SIRT1 binds to endogenous APE1. Co-immunoprecipitation of endogenous SIRT1 and APE1 in HEK
293 cells. (D) Co-localization of ﬂuorescent epitope-tagged SIRT1 and APE1 expressed in HEK 293 cells. Co-localization of extra-nucleolar (white
arrow) APE1 but not nucleolar (blue arrow) APE1 with SIRT1 is shown. (E) Hydrogen peroxide (H2O2) promotes binding of APE1 to SIRT1. H2O2
(500mM, 30min) increases co-precipitation of epitope-tagged SIRT1 in immunoprecipitates of epitope-tagged APE1 expressed in HEK 293 cells.
WCL: whole cell lysate. N-IgG: non-immune immunoglobulin. FLAG-APE1 and Myc-SIRT1 were expressed in A and B, DsRed-APE1 and EGFP-
SIRT1 in C, and DsRed-APE1 and Myc-SIRT1 in D.
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basal acetylation of APE1. Tagged APE1 was expressed
in HEK 293 cells and its acetylation on lysine residues
was determined in the presence and absence of SIRT1
overexpression. SIRT1 overexpression led to a decrease
in basal lysine acetylation of APE1 (Figure 2D).
In contrast to wild-type SIRT1, expression of the
dominant negative SIRT1(H363Y) increased acetylation
of APE1. In addition, treatment of cells with the SIRT1
inhibitor NAM increased basal lysine acetylation of APE1
(Figure 2E). However, addition of TSA to NAM-treated
cells did not further increase acetylation of APE1
(Figure 2E). This is in contrast to the synergistic eﬀect of
TSA and NAM on lysine acetylation of p53 (Figure 2E).
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Figure 2. SIRT1 deacetylates APE1. (A) In vitro deacetylation of recombinant APE1 by SIRT1. Recombinant APE1 enzymatically acetylated by the
p300 acetyltransferase was deacetylated by recombinant active SIRT1 in presence of the SIRT1 co-factor NAD
+ (1mM). Deacetylation was
inhibited by the SIRT1 inhibitor nicotinamide (NAM, 10 mM), but not the class I and II HDAC inhibitor Trichostatin A (TSA, 1mM).
(B) APE1 acetylated by the p300 acetyltransferase is deacetylated by SIRT1 in vivo.( C) Resveratrol inhibits p300-induced lysine acetylation of
exogenous APE1. (D) Expression of wild-type SIRT1 (WT) decreases and dominant negative SIRT1 (H363Y) increases, acetylation of exogenous
APE1 in HEK293 cells. (E) The SIRT1 inhibitor NAM and H2O2 increases acetylation of exogenous APE1 in HEK 293 cells. Cells were treated with
H2O2 (500mM), NAM (5 mM) and the class I and II HDAC inhibitor Trichostatin A (TSA: 5mM) for 30min. Values of lysine acetylated/total APE1
from a representative experiment, normalized to untreated cells, are shown. Acetylation of endogenous p53 is shown at bottom for comparison.
WCL: whole cell lysate. (F) TSA (5mM) and siRNA-mediated knockdown of endogenous SIRT1 increase lysine acetylation of endogenous APE1 in
HEK 293 cells. (G) Resveratrol suppresses basal lysine acetylation of APE1 in HEK 293 cells. (H) Activation of endogenous SIRT1 with resveratrol
antagonizes MMS-induced lysine acetylation of exogenous APE1.
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acetylation of exogenous APE1, knockdown of endog-
enous SIRT1 expression with siRNA promoted acet-
ylation of endogenous APE1 (Figure 2F). In comparison
with SIRT1 knockdown, addition of the class I and II
HDAC inhibitor TSA resulted in a smaller increase in
lysine acetylation of APE1 (Figure 2F). In addition, stim-
ulation of endogenous SIRT1 with resveratrol decreased
lysine acetylation of endogenous APE1 (Figure 2G). These
ﬁndings show that in addition to deacetylating APE1 that
is hyperacetylated by the p300 acetyltransferase, SIRT1
also regulates basal acetylation of APE1. In addition,
they suggest that class I and II HDAC inhibitors also
play a role, albeit lesser than SIRT1, in regulating basal
acetylation of APE1.
APE1 acetylation by genotoxic stress is
antagonized by SIRT1
Because we had noted that H2O2 increases the binding of
APE1 to SIRT1 (Figure 1E), we also asked whether this is
accompanied by a change in lysine acetylation of APE1.
In HEK 293 cells, H2O2 led to an increase in acetylation
of APE1 (Figure 2E). To determine whether the increase
in lysine acetylation of APE1 observed with H2O2 is a
phenomenon common to other genotoxic agents that
induce abasic DNA damage, we next examined the eﬀect
of methyl methanesulfonate (MMS), another well-known
genotoxic stress that results in abasic DNA sites. Similar
to the eﬀect of H2O2, MMS treatment for a short time
(4h) resulted in an increase in lysine acetylation of
endogenous APE1 (Figure 2H). Importantly, stimulation
of endogenous SIRT1 with the SIRT1 activator
resveratrol abrogated the increase in APE1 lysine
acetylation induced by MMS.
We next investigated the kinetics of APE1 acetylation
with genotoxic stress. A time course of treatment with
MMS revealed that APE1 acetylation was increased at
an early time point, followed by a decline to near basal
levels at later time points (Figure 3A). Interestingly, the
decline in APE1 acetylation at later times was accom-
panied by up-regulation of SIRT1 protein (Figure 3A).
This time-dependent progressive upregulation of SIRT1
with MMS was corroborated with SIRT1 mRNA
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Figure 3. SIRT1 is upregulated by MMS and antagonizes MMS-induced acetylation of APE1. (A) Reciprocal temporal relationship between MMS-
induced APE1 acetylation and SIRT1 expression. Time course of APE1 lysine acetylation and SIRT1 protein expression in HEK 293 cells challenged
with MMS. (B) MMS increases SIRT1 mRNA. Time course of SIRT1 mRNA upregulation in HeLa cells challenged with MMS. (C) MMS
increases SIRT1 promoter activity. Time course of human SIRT1 promoter induction in HeLa cells challenged with MMS. (D) SIRT1 inhibition
augments MMS-induced acetylation of APE1. Time course of APE1 lysine acetylation in HEK 293 cells pre-treated with the SIRT1 inhibitor
NAM (5mM) and challenged with MMS. (E) SiRNA-mediated suppression of SIRT1 in HEK 293 cells promotes MMS-induced APE1 acetylation.
Lysine acetylated/total APE1 ratio from a representative experiment is shown and is normalized to untreated control siRNA cells. WCL: whole cell
lysate.
Nucleic AcidsResearch, 2010, Vol.38,No. 3 837expression and SIRT1 promoter-reporter assays (Figure
3B and C). The reciprocal relationship between APE1
acetylation and SIRT1 expression suggested to us that
upregulation of endogenous SIRT1 may be a feedback
mechanism for regulation of APE1 acetylation induced
by MMS. Indeed, inhibition of endogenous SIRT1
activity resulted in more robust lysine acetylation of
APE1, even at later time points (Figure 3D). Moreover,
knockdown of endogenous SIRT1 also promoted lysine
acetylation of APE1 induced by MMS (Figure 3E).
These ﬁndings demonstrate an important role for
endogenous SIRT1 in antagonizing the lysine acetylation
of APE1 induced by the genotoxic agent MMS, and impli-
cate transcriptional upregulation of SIRT1 by MMS as an
endogenous feedback mechanism that modulates
genotoxic stress-induced APE1 acetylation.
Lysines 6 and 7 in APE1 are deacetylated by SIRT1
We then investigated the speciﬁc lysine residues in APE1
that SIRT1 targets for deacetylation. APE1 is acetylated
on lysine residues 6 and 7 at its N-terminus in response to
changes in extracellular calcium (16). We therefore looked
at these speciﬁc residues as targets of SIRT1. Lysines
6 and 7 in APE1 were mutated to non-acetylatable
arginines, individually or in concert, and these non-
acetylatable forms of APE1 were expressed in HEK 293
cells. Basal acetylation and change in acetylation induced
by NAM-mediated inhibition of endogenous SIRT1
activity was then examined and quantiﬁed on wild-type
as well as non-acetylatable APE1 lysine mutants.
Compared with wild-type protein, mutation of lysine 6
did not result in a signiﬁcant decrease in either basal or
NAM-induced acetylation of APE1 (Figure 4A).
However, APE1 that was mutated on lysine 7 did show
a signiﬁcant decrease in both basal and NAM-stimulated
acetylation, when compared with wild-type protein.
Moreover, APE1 that was non-acetylatable at both
lysines 6 and 7 showed an even greater decrease in basal
and NAM-induced acetylation. These ﬁndings show that
both lysines 6 and 7 are targeted for deacetylation by
SIRT1, and also suggest synergism between deacetylation
by SIRT1 of the two lysine residues. Consistent with this
notion, p300-stimulated lysine acetylation of APE1 was
essentially unchanged when lysine 6 was non-acetylatable,
diminished when lysine 7 was non-acetylatable, and
almost completely abolished when both lysines 6 and 7
were non-acetylatable (Figure 4B). However, because
replacement of both lysines 6 and 7 with non-acetylatable
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838 Nucleic Acids Research, 2010,Vol. 38,No. 3residues did not completely abolish the increase in
acetylation in response to NAM, deacetylation of lysines
other than 6 and 7 by SIRT1 remains a possibility.
APE1 mediates SIRT1-dependent protection against
genotoxic stress
Next, we determined the relationship between APE1 and
SIRT1 in cytoprotection against genotoxic stress. First, we
determined if APE1 and SIRT1, independently, protect
cells from such stress. Knockdown of endogenous
SIRT1 increased susceptibility of HeLa cells to apoptosis
induced by MMS and H2O2 (Figure 5A). Similarly,
knockdown of endogenous APE1 also made HeLa cells
more vulnerable to death by H2O2 and MMS (Figure 5B).
Then, to determine if APE1 mediates SIRT1-dependent
cytoprotection, the eﬀect of increasing APE1 expression
on the vulnerability to cell death associated with knock-
down of SIRT1 was examined. In HeLa cells in which
SIRT1 expression was knocked down, susceptibility to
MMS-induced apoptosis was rescued by adenoviral
overexpression of APE1 (Figure 5C). These ﬁndings dem-
onstrate that both endogenous SIRT1 and APE1 protect
from cell death induced by genotoxic stimuli, and suggest
that stimulation of APE1 activity is responsible for the
cytoprotection conferred by SIRT1. However, we cannot
deﬁnitively conclude the role of SIRT1-mediated APE1
deacetylation in protection against genotoxic stress.
APE1 is essential for repair of abasic DNA. Therefore,
to further establish a functional link between cellular
APE1 and SIRT1, we examined the role of SIRT1 in the
cellular DNA repair machinery. The eﬀect of SIRT1
knockdown on the formation of apurinic/apyrimidinic
DNA sites generated by genotoxic stress was determined.
Knockdown of SIRT1 increased cellular apurinic/
apyrimidinic sites in response to MMS (Figure 5D). This
eﬀect was similar to that observed with knockdown of
APE1. These ﬁndings show that endogenous SIRT1, like
endogenous APE1, plays an important role in the repair of
abasic DNA sites.
SIRT1 promotes the association of APE1 and XRCC1
We then sought to further elucidate the APE1-mediated
mechanism responsible for cytoprotection conferred by
SIRT1. Hypothesizing that SIRT1, by deacetylating
APE1, may modulate its binding to other proteins that
play a part in the BER pathway, we sought out known
binding partners of APE1. X-ray cross-complementing-1
(XRCC1) is a protein that binds with enzymes involved at
each step in the BER pathway (37), and functions to
organize proteins at the damaged DNA site. XRCC1
binds to APE1 and the N-terminal region of APE1 has
been shown to mediate this interaction (38). Knowing that
the N-terminal lysine residues of APE1 are targeted for
deacetylation by SIRT1 prompted us to investigate
whether SIRT1 aﬀects binding of APE1 to XRCC1. In
HeLa cells, APE1 co-precipitated with XRCC1 (Figure 6A).
Inhibition of endogenous SIRT1 with NAM suppressed
binding of APE1 to XRCC1 (Figure 6A). Conversely,
stimulation of endogenous SIRT1 activity with resveratrol
promoted the association of APE1 and XRCC1.
Moreover, resveratrol-stimulated association of APE1
and XRCC1 was abrogated by knockdown of endogenous
SIRT1 (Figure 6B). These ﬁndings indicate that SIRT1
promotes the association of APE1 and XRCC1.
Armed with the knowledge that SIRT1 facilitates the
interaction of APE1 and XRCC1, and SIRT1 antagonizes
MMS-induced acetylation of APE1, we then asked
whether MMS aﬀects the binding of APE1 to XRCC1,
and whether SIRT1 modulates this eﬀect. Challenge
with MMS increased the association of APE1 and
XRCC1 in HeLa cells (Figure 6C). However, inhibition
of endogenous SIRT1 activity with NAM negated MMS-
induced increase in APE1-XRCC1 binding (Figure 6D).
Because NAM may have oﬀ-target eﬀects, we also
examined the eﬀect of SIRT1 knockdown on MMS-
stimulated binding of APE1 to XRCC1. Knockdown of
SIRT1 with siRNA suppressed MMS-stimulated binding
of APE1-XRCC1 (Figure 6E). Collectively, these ﬁndings
suggest that genotoxic stress upregulates SIRT1 and
acetylates APE1, and the increase in SIRT1 expression
acts to deacetylate APE1, thereby allowing formation of
the APE1:XRCC1 complex in the BER pathway.
Because SIRT1 targets the N-terminal lysine residues in
APE1 for deacetylation, we next asked whether these
lysine residues mediate the stimulatory eﬀect of SIRT1
on binding of APE1 to XRCC1. When compared with
wild-type protein, APE1 that was non-acetylatable at
lysines 6 and 7 bound with greater aﬃnity to XRCC1
under basal conditions (Figure 6E). In addition, MMS
stimulated binding of the non-acetylatable APE1 to
XRCC1 to a greater extent than it did of wild-type
APE1 (Figure 6E). Importantly, unlike its eﬀect on
MMS-stimulated binding of wild-type APE1 to XRCC1,
knockdown of SIRT1 did not suppress MMS-stimulated
binding of non-acetylatable APE1 to XRCC1 (Figure 6E).
These ﬁndings show that non-acetylatable APE1 binds
preferentially to XRCC1, both under resting conditions
and with genotoxic stress. Moreover, they suggest that
rendering lysines 6 and 7 non-acetylatable may impact
on additional residues within this N-terminal region,
thus facilitating genotoxic stress-induced binding of
APE1 to XRCC1.
Cellular AP endonuclease activity is regulated by SIRT1
Finally, we asked whether SIRT1-mediated increase in
binding of APE1 to XRCC1 is associated with an
increase in the abasic endonuclease activity in protein
complexes containing XRCC1. AP endonuclease activity
was measured in XRCC1 immunoprecipitates from lysates
of APE1-expressing HeLa cells that were treated with
NAM or resveratrol. Compared with untreated cells,
treatment with NAM led to a decrease, whereas treatment
with resveratrol increased, the AP endonuclease activity of
XRCC1 immunoprecipitates (Figure 6F). In addition,
siRNA-mediated knockdown of SIRT1 suppressed AP
endonuclease activity of XRCC1 immunoprecipitates
(Figure 6G). However, neither p300-induced acetylation,
nor SIRT1-induced deacetylation, changed the in vitro AP
endonuclease activity of recombinant APE1 (Figure 6H).
These ﬁndings are consistent with the notion that
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Nucleic AcidsResearch, 2010, Vol.38,No. 3 841SIRT1-mediated deacetylation of APE1 does not directly
aﬀect the AP endonuclease activity of APE1, but rather,
SIRT1 stimulates cellular AP endonuclease activity by
promoting the association of APE1 to XRCC1.
DISCUSSION
The principal ﬁndings in this study are (i) APE1 is a target
for deacetylation by SIRT1, (ii) SIRT1 promotes associa-
tion of APE1 with XRCC1, (iii) SIRT1 stimulates cellular
AP endonuclease activity, and (iv) APE1, in part, mediates
the cytoprotective eﬀect of SIRT1. These ﬁndings add to
the growing evidence supporting a role for SIRT1 in main-
tenance of genomic stability (39,40). SIRT1 serves this role
through deacetylation-mediated regulation of multiple
target proteins that play a part in orchestrating cell cycle
arrest and apoptosis in response to DNA damage (21,26–
28,35,41). Despite multiple known targets of SIRT1, few
are directly involved in DNA repair. NBS1, a component
of the nuclease complex that senses and participates in the
response to double-stranded DNA breaks, is one target of
SIRT1 that plays a direct role in DNA repair (29). Our
ﬁndings add APE1 to the target proteins of SIRT1 that
are directly involved in repair of damaged DNA. Based on
our experimental ﬁndings we postulate a model in which
SIRT1 plays an important role in the BER pathway, both
under basal conditions and with genotoxic stress (Figure
7). This model predicts that SIRT1 tonically binds to and
deacetylates APE1, and this physical and functional inter-
action increases when the demand for BER increases such
as with genotoxic insults.
Prior work has demonstrated that APE1 is acetylated
by the p300 acetyltransferase on lysine 6 and/or 7, and
APE1 that is non-acetylatable on these residues is
impaired in its capacity to bind to the nCaRE element
in the PTH promoter, and repress PTH promoter
activity in response to an increase in extracellular Ca
2+
concentration (16). This study also showed that inhibition
of class I and II HDACs with TSA increased lysine
acetylation of APE1 to some degree, suggesting that
acetylation of APE1 is regulated by such HDAC.
However, despite stimulating lysine acetylation of APE1,
TSA did not promote the ability of APE1 to repress PTH
promoter activity with increase in extracellular Ca
2+.
These ﬁndings suggest that direct deacetylation of APE1
by class I and II HDACs does not play a major part in the
negative calcium response mediated by APE1. Our
ﬁndings are consistent with this previous report in that
they show that class I and II HDACs do play some part
in modulating the basal lysine acetylation of APE1. Other
studies have shown a more robust increase in lysine
acetylation of APE1 with inhibition of class I and II
HDAC for a longer period of time (17), and this may
reﬂect diﬀerence in deacetylation kinetics between such
HDAC and SIRT1. Although we do not underestimate
the importance of class I and II HDAC in regulating
APE1 acetylation, our data also points toward a novel
role for the class III HDAC SIRT1 in inhibiting both
basal and genotoxic stress-induced lysine acetylation of
APE1, and suggest that, similar to the scenario with p53
acetylation on lysine 382 (22), SIRT1 and certain class I
and II HDAC may target some of the same lysine residues
in APE1. Moreover, our data show for the ﬁrst time that
acetylation of these lysine residues is reversible, and
identify SIRT1 as one of the deacetylases responsible for
this.
APE1 forms a multi-molecular DNA repair complex
directed toward abasic DNA sites. XRCC1, which may
serve as a scaﬀolding protein in this complex, is known
to interact with APE1 through the N-terminal region of
APE1, and stimulates the AP endonuclease activity
of APE1 (38). The ﬁnding that the acetylation status of
two lysine residues in the N-terminal region of APE1 is
important in determining its binding to XRCC1 is consis-
tent with recent reports showing that this region, which
has an intrinsically disordered structure (2,42), is essential
for its interaction with other nuclear proteins. A recent
study shows that the interaction of APE1 with
nucleophosmin-1 (NPM1), a nucleolar protein, is
mediated by the 33 amino acid N-terminal region of
APE1 (43). Moreover, this interaction stimulates the AP
endonuclease activity of APE1 in a cell-free system, a
ﬁnding that suggests a direct eﬀect on NPM1 on APE1
endonuclease activity. Our experimental data did not
show an eﬀect of acetylation or SIRT1-induced
deacetylation on the endonuclease activity of
recombinant APE1 in vitro, nor did we ﬁnd that the
acetylation of APE1 in vitro changes the polymerase
activity of b-polymerase (T. Yamamori and K. Irani,
unpublished observations), another enzyme in the BER
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842 Nucleic Acids Research, 2010,Vol. 38,No. 3pathway that physically associated with APE1 (5). These
ﬁndings support our hypothesis that SIRT1 impacts on
cellular AP endonuclease activity indirectly by modulating
the interaction of APE1 with other proteins of the BER
machinery, but does not directly change the activity
of APE1 or APE1-associated DNA repair enzymes.
Nevertheless, based on the interesting ﬁnding that the
interaction of APE1 with NPM1 directly stimulates
its endonuclease activity, it would be worthwhile to see
if acetylation and SIRT1-induced deacetylation aﬀects
APE1 endonuclease activity stimulated by NPM1
through modulation of APE1-NPM1 binding. Such
studies may be especially revealing in light of the roles
of NPM1 in ribosomal biogenesis (43), and SIRT1 in
ribosomal RNA synthesis (44).
APE1 also interacts with the Y-box-binding protein 1
(YB-1) enhancing its binding to the Y-box element, and
stimulating multi-drug resistance (MDR1) gene expression
(45). This interaction also occurs though the N-terminal
region of APE1, reinforcing the importance of this region
in binding of APE1 to other proteins. Notably, APE1 that
is non-acetylatable on lysines 6 and 7 displays lesser
binding to YB-1 than wild-type protein. Our ﬁndings
suggest that APE1 that is deacetylated by SIRT1
preferentially binds to XRCC1. We did not examine the
role of acetylation in mediating the interaction of APE1
with SIRT1. However, we did observe that H2O2
increased acetylation of APE1 and its association with
SIRT1, hinting at the possibility that as far as the
APE1:SIRT1 interaction is concerned, acetylation of
APE1 may facilitate its binding to SIRT1. A similar
increase in binding of SIRT1 to FOXO transcription
factors, a target of SIRT1, with H2O2 has been reported
(46). Increase in this APE1:SIRT1 interaction by
genotoxic stress would allow the deacetylation of APE1
thus permitting APE1:XRCC1 binding. It is not clear
what purpose acetylation of APE1 may serve in the
context of genotoxic insults. However, one can hypothe-
size that the degree of acetylation of APE1 may serve as a
switch that guides the cell down one of two paths:
hyperacetylation of APE1 may induce a transcriptional
program of apoptosis, perhaps by activating transcription
factors as it does YB-1, whereas SIRT1-stimulated
hypocetylation may promote DNA repair and cell
survival. This scenario, if true, would be reminiscent of
how acetylation and SIRT1-mediated deacetylation of
FOXO transcription factors guides the cell toward a fate
of survival or death (26).
The eﬀect of genotoxic agents on the acetylation of
APE1 deserves attention. Although both H2O2 and
MMS increased acetylation of APE1, this eﬀect was
modest and became much more apparent when endo-
genous SIRT1 activity was inhibited. Importantly, MMS
increased SIRT1 expression and this increase followed a
time course that was reciprocal to MMS-stimulated APE1
acetylation. These ﬁndings suggest that endogenous
SIRT1 functions to negate the acetylation of APE1 by
these genotoxic stimuli. Although these studies establish
the role of SIRT1 in negatively regulating acetylation of
APE1 in response to these genotoxic stimuli, we did
not explore the mechanism for acetylation of APE1 by
these stimuli. It is noteworthy however, that MMS
increases the acetylation of Werner (WRN), another
important protein in base excision repair pathways, in a
p300-dependent fashion (47), suggesting that H2O2 and
MMS-induced acetylation of APE1 may also be
mediated by p300. However, we cannot exclude the pos-
sibility that other acetyltransferases may also target APE1
for lysine acetylation in response to DNA damaging
agents, as has been observed for p53 acetylation (48).
We observed that MMS leads to transcriptional
upregulation of SIRT1 expression. SIRT1 is known to
be transcriptionally induced by the DNA damaging
agent etopside (41). This transcriptional induction is
mediated by the transcription factor E2F1, with a
conserved E2F1-binding element present in the human
and mouse SIRT1 promoters. Therefore, it is likely that
induction of SIRT1 by MMS is also dependent on E2F1.
In support of this, reporter analysis of truncated human
SIRT1 promoters have shown that the sequence 115 bp
upstream of the transcription start site, which includes the
E2F1 binding site, is suﬃcient for induction of promoter
activity by MMS (T. Yamamori and K. Irani, unpublished
observations).
Finally, although our study focused on exploring the
consequence of the APE1:SIRT1 interaction on lysine
acetylation of APE1, it is tempting to speculate that this
association may also facilitate a yet unknown eﬀect of
APE1 on SIRT1. One attractive possibility is that this
interaction may allow the regulation of SIRT1 by APE1,
similar to the role that APE1 plays in the regulation of
AP-1 transcriptional activity through its physical associa-
tion with thioredoxin (49).
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